SecBot SecBot
424B5 ·Filed Apr 1, 2026

INO

INOVIO PHARMACEUTICALS, INC.
BEARISH
Impact 6/10
Horizonmonths Processed7mo ago SEC0001193125-26-138636
Notable filing: 424B5
Actionable Insight ▼ Bearish

Monitor FDA's decision on INO-3107's accelerated approval pathway by the October 30, 2026 PDUFA date, as this will be a critical catalyst. The stock is likely to remain under pressure due to the company's cash constraints and dilutive capital raising, with any positive FDA developments potentially providing temporary relief.

DirectionBearish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.13
T+0 close · Apr 1, 2026 · via day close
Latest settled
−2.65%
T+60 · $1.10
Vs SPY
−16.81%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 2 $1.13entry
  2. T+1 · 8mo ago 0.00%α −0.48% · $1.13
  3. T+5 · 7mo ago −6.19%α −9.81% · $1.06
  4. T+20 · 7mo ago −0.89%α −10.76% · $1.12
  5. T+60 · 5mo ago −2.65%α −16.81% · $1.10
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Inovio Pharmaceuticals is conducting a public offering of common stock and accompanying warrants to raise capital, primarily to prepare for a potential commercial launch of its lead candidate INO-3107 for recurrent respiratory papillomatosis. The offering includes immediate dilution for new investors and comes amid significant uncertainty about FDA approval under the accelerated pathway, with the company acknowledging substantial doubt about its ability to continue as a going concern.

Key Facts

  • Company is raising capital through a public offering of common stock and warrants
  • Proceeds will be used for commercial launch preparation of INO-3107, confirmatory trial, and pipeline development
  • FDA has accepted BLA for INO-3107 under accelerated approval but questioned eligibility, creating significant regulatory uncertainty
  • Company acknowledges substantial doubt about its ability to continue as a going concern
  • New investors will experience immediate dilution as offering price exceeds net tangible book value
  • No established trading market for the warrants being offered

Financial Impact

The offering will provide capital to fund operations, but exact amount undisclosed. New investors face immediate dilution as offering price exceeds net tangible book value per share of $0.35

dilutioncashequity

Risk Factors

  • FDA may deny accelerated approval for INO-3107
  • Company may not have sufficient capital to fund operations
  • Significant dilution for new investors in the offering
  • Competition from approved therapy PAPZIMEOS

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001193125-26-138636
Document: 0001193125-26-138636-index-headers.html0001193125-26-138636
Document: 0001193125-26-138636-index.html0001193125-26-138636
Document: 0001193125-26-138636.txt0001193125-26-138636

Track record

20 reports on INO

Performance horizon

7 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +46.23% at T+20 after the Jul 2, 2026 report. 8 of 14 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.39 Now $1.40 +0.72% settles Nov 24
  2. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $1.40 Now $1.40 −0.01% settles Nov 24
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.41 Now $1.40 −0.71% settles Nov 23
  4. Nov 10, 20266d ago 8-K Bearish 5/10 Entry $1.48 Now $1.40 +5.08% settles Nov 18
  5. Nov 9, 20267d ago 8-K Bearish 5/10 Entry $1.51 to $1.40 Now $1.40 +7.28% ▲ +7.28% +5.59% vs SPY
  6. Nov 6, 202610d ago 424B5 Bearish 5/10 Entry $1.51 to $1.40 Now $1.40 +7.28% ▲ +7.28% +5.59% vs SPY
  7. Nov 5, 202611d ago Press Release Bearish 6/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
  8. Nov 5, 202611d ago 8-K Bearish 5/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
  9. Nov 5, 202611d ago 424B5 Bearish 4/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
  10. Nov 5, 202611d ago Press Release Bearish 4/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 6h 21m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 2, 2026